Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. - Wikidata - thesis-toulmin - TriplyDB

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

http://www.wikidata.org/entity/Q35000771

about

Pharmacogenetics and outcome with antipsychotic drugs Pharmacogenetics of antipsychotics.Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia.Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders Sulfotransferase 4A1 Haplotype 1 (SULT4A1-1) Is Associated With Decreased Hospitalization Events in Antipsychotic-Treated Patients With Schizophrenia.Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.Pharmacogenetics of olanzapine metabolism.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.Pharmacogenetics of second-generation antipsychotics.Genetic variation in CYP3A43 is associated with response to antipsychotic medication.The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.Human genetic variation of CYP450 superfamily: analysis of functional diversity in worldwide populations.Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.

P2860

Q26852807-54180E1E-290A-47C1-809F-4CB5D81BBD23 Q33836837-AEA3F767-EF66-423A-A7B4-46802E97D526 Q33923615-02665612-7E2E-45FD-8BF1-FE47809BFFE3 Q34391577-8FA37657-6748-492E-A537-639F2C763B15 Q36302841-F165E37D-EA2A-471C-88C1-371D936B4DD3 Q37344782-BBB1B5F3-9116-4AFA-BBEC-5CA2EA447A39 Q38127716-3687684D-7CA5-48C4-AEED-587FD4684097 Q38154915-E2F54CC0-EC96-4ACB-9F36-106EC1F77965 Q38217628-EC0548D9-E2DB-4474-8689-E65BE94ED79B Q38242595-02316040-5E0B-405C-88BA-08DEBB2C3E9C Q40943084-D85619F4-8A81-4608-A13B-215451F191C6 Q43555751-482DEA82-98D1-4E8E-B89D-AE3E90195E49 Q50736144-AA3F5753-D66E-4EE3-A38B-37B8EFAE88C6

P2860

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

http://www.wikidata.org/entity/Q35000771

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

@ast

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

@en

type

label

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

@ast

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

@en

prefLabel

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

@ast

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

@en

P1433

Q35000771-7922DCB3-9625-451E-892C-A892437C0911

P1476

Q35000771-98B3B38B-5445-42B9-9F5C-6C146EC07561

P2093

Q35000771-11BA9452-E1CB-48E0-8306-1DA910C68949

Q35000771-72806A74-EDA4-4DD6-8602-D5DC8D881E4D

Q35000771-84D9910C-5766-475B-A6D3-44497E981365

Q35000771-A7E4B91D-7114-4520-9C1D-59DA391E1E08

Q35000771-DEE69CDB-AAE4-4287-B5CD-2E027223A89C

Q35000771-FC53D8C4-96BA-492C-BCE5-64312400A090

P2860

Q35000771-053BC22B-B9D6-4611-97E0-B1B0A2BCF860

Q35000771-06F00CD6-BB89-46C8-A70B-6219E30B59AB

Q35000771-1B54D400-4E21-4B34-B15A-9CC5D310227F

Q35000771-2D4CB928-A4FA-4396-8F1F-E4E02BDAC2E3

Q35000771-3D8ED025-D721-4ADF-A376-FD56F61D99F8

Q35000771-41F30152-034A-4D83-B875-83188D97E5D6

Q35000771-46070FA9-BF7C-4F32-9C45-B3F4AE85BC7A

Q35000771-47858901-8B2D-4512-BF45-54305786577D

Q35000771-47DE9957-7EBB-437B-B9A2-67C5293A65D2

Q35000771-4C9CE4E4-2B4B-48E4-81EA-1300C015C256

P2888

Q35000771-52E34681-AFB2-428E-8B36-D18A041F5093

P304

Q35000771-10E218B9-329B-4F11-A3F9-EDECAB7C8EFE

P31

Q35000771-3D840B70-F32F-4D63-938B-A8FCC7CFD4C2

P356

Q35000771-463927AD-9B74-4126-ADC7-6930AEAAFACB

P407

Q35000771-F0C4AB37-F36F-4306-BA42-2D288FD834A9

P433

Q35000771-8BFFD4EB-65B9-4780-AD4A-E72B74217C94

P478

Q35000771-08C32B70-1E90-4832-9719-893406FB1B31

P577

Q35000771-D596352E-0CBD-4770-8185-540C5F41DC57

P5875

Q35000771-0D7F3F69-301A-4404-A3A3-37EFF07F9D80

P698

Q35000771-7FCFE2EE-7B29-4316-A8F4-D73A6F8C8C3E

P932

Q35000771-52CBD19A-C814-4DC7-8494-4CCD5E7E9086

P356

P1433

Molecular Psychiatry

P1476

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

@en

P2093

B G Pollock

http://www.w3.org/2001/XMLSchema#string

D R Weinberger

http://www.w3.org/2001/XMLSchema#string

F Zhang

http://www.w3.org/2001/XMLSchema#string

J J Lowy

http://www.w3.org/2001/XMLSchema#string

K L Bigos

http://www.w3.org/2001/XMLSchema#string

R R Bies

http://www.w3.org/2001/XMLSchema#string

P2860

PLINK: a tool set for whole-genome association and population-based linkage analyses

The International HapMap Project

Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Sequence diversity and haplotype structure at the human CYP3A cluster

Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite

cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450

Genomewide association for schizophrenia in the CATIE study: results of stage 1

Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients.

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

P2888

P304

620-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MP.2011.38

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51076281

http://www.w3.org/2001/XMLSchema#string

P698

21519338

http://www.w3.org/2001/XMLSchema#string

P932

3100476

http://www.w3.org/2001/XMLSchema#string